Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service

References

• MooreRDBartlettJGDramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practiceClin Infect Dis201153660060421844006
   PubMed Web of Science ®Google Scholar
• ReinaESan MiguelRLarreaNGarciaPNapalVPotential for simplification of HIV treatment with boosted protease inhibitor monotherapyInt J Clin Pharm201234691191623007692
   PubMed Web of Science ®Google Scholar
• FordNFlexnerCVellaSRipinDVitoriaMOptimization and simplification of antiretroviral therapy for adults and childrenCurr Opin HIV AIDS20138659159924100871
   PubMed Web of Science ®Google Scholar
• LlibreJMCardonaGSantosJRAntiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in SpainClinicoecon Outcomes Res2013521522123723714
   PubMedGoogle Scholar
• ElziLMarzoliniCFurrerHSwiss HIV Cohort StudyTreatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008Arch Intern Med20101701576520065200
   PubMed Web of Science ®Google Scholar
• ArribasJRClumeckNNelsonMHillAvan DelftYMoecklinghoffCThe MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA copies/mL at baselineHIV Med201213739840522413874
   PubMed Web of Science ®Google Scholar
• ValantinMALambert-NiclotSFlandrePMONOI ANRS 136 Study GroupLong-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 studyJ Antimicrob Chemother201267369169522160145
   PubMed Web of Science ®Google Scholar
• BiermanWFvan AgtmaelMANijhuisMDannerSABoucherCAHIV monotherapy with ritonavir-boosted protease inhibitors: a systematic reviewAIDS200923327929119114854
   PubMed Web of Science ®Google Scholar
• PulidoFArribasJRDelgadoROK04 Study GroupLopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVAIDS2008222F1F918097218
   PubMed Web of Science ®Google Scholar
• d’Arminio MonforteAGianottiNCozzi-LepriAICONA Foundation CohortDurability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/mL in an observational settingAntivir Ther201419331932424036891
   PubMed Web of Science ®Google Scholar
• CossariniFSalpietroSGalliLMonotherapy with atazanavir as a simplification strategy: results from an observational studyJ Acquir Immune Defic Syndr2012603e101e10322728751
   PubMed Web of Science ®Google Scholar
• KarlströmOJosephsonFSönnerborgAEarly virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapyJ Acquir Immune Defic Syndr200744441742217159658
   PubMed Web of Science ®Google Scholar
• CastagnaASpagnuoloVGalliL48-weeks outcomes of atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: interim analysis results of the MODAT Study14th European AIDS ConferenceOctober 16–19, 2013Brussels, Belgium Abstract PS4/2. Available from: http://eacs.multi-learning.com/eacs/2013/14th/39215/antonella.castagna.48-weeks.outcomes.of.atazanavir.ritonavir.monotherapy.as.html?history_id=689784Accessed May 9, 2014
   Google Scholar
• Ministry of Health, Commissione Nazionale per la lotta contro l’AIDS, Consulta delle Associazioni per la lotta contro l’AIDS, Società Italiana di Malattie Infettive e TropicaliLinee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1Ministero della Salute2013 Italian. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2074_allegato.pdfAccessed May 9, 2014
   Google Scholar
• CasadoJLde la CalleCdel PalacioMPerez-ElíasMJMorenoAMorenoSShort communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of conceptAIDS Res Hum Retroviruses201329358859123163811
   PubMed Web of Science ®Google Scholar
• Decreto del commissario ad acta 13 gennaio 2014, n 2Aggiornamento del decreto “Razionalizzazione dell’uso di farmaci per la terapia antiretrovirale HIV” Available from: http://www.regione.lazio.it/binary/rl_sanita/tbl_normativa/Decr_U00002_13_1_13_aggiornamento_terapia_HIV.pdfAccessed May 9, 2014
   Google Scholar
• Di GiambenedettoSFabbianiMColafigliMSafety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)J Antimicrob Chemother20136861364137223372058
   PubMed Web of Science ®Google Scholar
• MauskopfJASullivanSDAnnemansLPrinciples of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysisValue Health200710533634717888098
   PubMed Web of Science ®Google Scholar
• RaimondoMCamoniLRegineVCaratteristiche delle persone che vivono con L’HIV e con L’AIDS in Italia [Characteristics of people living with HIV and AIDS in Italy]Not Ist Super Sanita2013267–836 Italian
   Google Scholar
• Directorate General for Health of Lombardy Region D.d.g. March 1, 2013 – 1725 – Approvazione del documento avente ad oggetto “Percorso diagnostico terapeutico (PDT) del paziente affetto da malattia HIV/AIDS Available from: http://www.ao.lodi.it/infoglue-DeliverLive/digitalAssets/102/102169_Percorso_diagnostico_terapeu-tico_del_paziente_affetto_da_malattia_HIV_AIDS_BURL_4_3_2013.sflb.pdfAccessed August 1, 2014
   Google Scholar
• Agenzia Italiana del FarmacoL’uso dei farmaci in Italia – Rapporto Nazionale Anno 2012Roma2013 Available from: http://www.agenziafarmaco.gov.it/sites/default/files/Rapporto_OsMed_2012.pdfAccessed May 9, 2014
   Google Scholar
• AngelettiCPezzottiPAntinoriAAntiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment startHIV Med201415316517424495188
   PubMed Web of Science ®Google Scholar